CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematology-oncology fellows, urologists and other healthcare providers involved in the treatment of prostate cancer.
  
  LEARNING OBJECTIVES

  • Appraise published research on the optimal management of biochemical recurrence after local treatment for prostate cancer, and counsel appropriate patients regarding the potential benefits of systemic therapy.
  • Evaluate the published research database supporting the FDA approvals of secondary hormonal agents for the management of nonmetastatic castration-resistant prostate cancer, and apply this information in the discussion of nonresearch treatment options.
  • Explore available data with treatment intensification with cytotoxic therapy, secondary hormonal therapy or combinations of these approaches for metastatic hormone-sensitive prostate cancer, and effectively integrate these strategies into current clinical management algorithms.
  • Establish an evidence-based approach to the selection and sequencing of available therapeutic options for patients with metastatic castration-resistant prostate cancer (mCRPC), considering age, comorbidities, prior therapeutic exposure and other relevant clinical and biological factors.
  • Assess the available research database supporting the use of PARP inhibitors as monotherapy or in combination with androgen receptor pathway inhibitors for patients with mCRPC harboring a homologous recombination repair gene alteration, and discern how to optimally incorporate these agents into current clinical management algorithms.
  • Recall the design of ongoing clinical trials evaluating other novel agents and strategies for prostate cancer, and counsel appropriate patients about availability and participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Video Program: Research To Practice designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 2.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.
  
  AMERICAN BOARD OF SURGERY (ABS) — CONTINUOUS CERTIFICATION (CC)
  Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.
  
  Please note, these programs have been specifically designed for the following ABS practice area: complex general surgical oncology.
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ASCO2024/Prostate/Video/CME.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Neeraj Agarwal, MD, FASCO
  Professor of Medicine
  Senior Director for Clinical Research
  Huntsman Cancer Institute Presidential Endowed Chair of Cancer Research
  Director, Center of Investigational Therapeutics
  Director, Genitourinary Oncology Program
  Huntsman Cancer Institute, University of Utah (NCI-CCC)
  Salt Lake City, Utah
  
  No relevant conflicts of interest to disclose.
  
  Emmanuel S Antonarakis, MD
  Clark Endowed Professor of Medicine
  Division of Hematology, Oncology and Transplantation
  University of Minnesota
  Minneapolis, Minnesota
  
  Advisory Committees: Aadi Bioscience, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Curium, Janssen Biotech Inc, Merck, Pfizer Inc, Sanofi, Tango Therapeutics, Tempus; Consulting Agreements: EcoR1 Capital LLC, Hookipa Pharma Inc, Lilly, Menarini Silicon Biosystems, Z-Alpha; Contracted Research: Astellas, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Clovis Oncology, MacroGenics Inc, Merck, Novartis, Orion Corporation, Seagen Inc; Patent Holder: QIAGEN.
  
  Tanya B Dorff, MD
  Professor of Medicine
  Vice Chair for Clinical Affairs
  Department of Medical Oncology and Therapeutics Research
  Section Chief, Genitourinary Cancer Program
  City of Hope National Medical Center
  Los Angeles, California
  
  Advisory Committees: Astellas, AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc, Sanofi; Consulting Agreement: Bayer HealthCare Pharmaceuticals.
  
  Matthew R Smith, MD, PhD
  Claire and John Bertucci Endowed Chair in Genitourinary Cancers
  Professor of Medicine
  Harvard Medical School
  Director, Genitourinary Malignancies Program
  Massachusetts General Hospital Cancer Center
  Boston, Massachusetts
  
  Advisory Committees: Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Lilly, Pfizer Inc; Consulting Agreements: Ambrx, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Lilly, Pfizer Inc; Contracted Research (to Institution): Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Lilly, Pfizer Inc; Stock Options/Ownership — Public Company:Ambrx.
  
  MODERATOR
  Andrew J Armstrong, MD, ScM
  Professor of Medicine, Surgery, Pharmacology and Cancer Biology
  Director of Research
  Duke Cancer Institute Center for Prostate and Urologic Cancers
  Divisions of Medical Oncology and Urology
  Duke University
  Durham, North Carolina
  
  Advisory Committees: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Clovis Oncology, Exelixis Inc, GoodRx, Merck, Myovant Sciences, Novartis, Pfizer Inc, Z-Alpha; Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Dendreon Pharmaceuticals Inc, Epic Sciences, Exact Sciences Corporation, Exelixis Inc, Forma Therapeutics, GoodRx, Janssen Biotech Inc, Merck, Myovant Sciences, Novartis, Pfizer Inc, Z-Alpha; Contracted Research: Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Celgene Corporation, Dendreon Pharmaceuticals Inc, Forma Therapeutics, Janssen Biotech Inc, Merck, Novartis, Pfizer Inc; Nonrelevant Financial Relationships: National Cancer Institute, National Institutes of Health, Prostate Cancer Foundation/Movember, US Department of Defense.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Merck.
  
  Release date: June 2024
  Expiration date: June 2025
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.